Atossa Genetics Inc (NASDAQ: ATOS) is having an overwhelmingly strong start to the trading session in the pre-market hours and for good reason. The company announced positive data with regard to a key clinical trial. Of course, this led to excitement among investors. Today, we’ll talk about the news, what we’re seeing from the stock, and what we’ll be watching for with regard to ATOS ahead.
ATOS Gains On Coming Presentation
Atossa Genetics is having an incredibly strong start to the trading session in the pre-market hours, and for good reason. The company issued a press release announcing data from a key Phase 1 clinical trial. The trial was a Phase 1 study of the company’s proprietary oral Endoxifen. Endoxifen is an active metabolite of tamoxifen, an FDA approved drug. Tamoxifen is currently being used as a treatment for breast cancer and as a cancer prevention treatment for high-risk patients. The additional data included:
- According to the ATOS release, the median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of the treatment came to 7 days.
- The company also said that the median time for patients in the study to reach the maximum serum level of Endoxifen after taking the treatment ranged from 4 to 8 hours. This figure was largely dependent on the size of the dose.
In a statement, Steve Quay, Ph.D., MD, President and CEO at ATOS, had the following to offer:
These additional findings are important for several reasons. Breast cancer patients do not typically want to wait weeks or even months for the current standard of care, oral tamoxifen, to take effect. Our study data indicates that our proprietary oral Endoxifen reaches a steady-state in about 7 days, while the literature indicates that it can take 50-200 days for tamoxifen to reach a steady state, keeping in mind that a breast cancer tumor can double in size in as little as 29 days. Not only does it take up to several months for oral tamoxifen to take effect, oral tamoxifen also does not benefit up to 50% of patients, partly because many patients cannot metabolize tamoxifen. For these reasons, we believe our oral Endoxifen may reduce the incidence of this deadly disease and fundamentally change the paradigm for breast cancer treatment.”
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!